Two big biotechs have been big busts for investors so far in 2017. Shares of Biogen (NASDAQ: BIIB) and Gilead Sciences (NASDAQ: GILD) are both down year to date, with Gilead’s shareholders experiencing the worse pain.
Should long-term investors consider either one of these biotech stocks? If so, which one is the better choice? Here are the cases for Biogen and Gilead Sciences.
Image source: Getty Images.